Drugs / Natura-alpha
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02286518 | Nov 2014 → Apr 2015 | — | Takeda | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01216280 | Jul 2010 → Jul 2011 | ulcerative colitis | Natrogen Therapeutics International, Inc | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Natura-alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01216280 ↗ |
| Known as | TAK-114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02286518 ↗ |
| Route | Oral | “10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.” NCT01216280 ↗ |